|
CAS:152923-56-3
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性: Daclizumab (Zenapax) 是一种人源化单克隆抗体,可阻断 CD25(高亲和力白细胞介素 2 受体 (IL-2R-HA) 的 α 亚基)。 Daclizumab (Zenapax) 可逆地结合 CD25 并阻止 IL-2 与 IL-2R-HA 的相互作用。 Daclizumab (Zenapax) 可用于多发性硬化症的研究[1]。
参考文献:[1]. Stanley L Cohan, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-20 06:13
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社